Key Highlights
- Total net Revenue for the nine months ended September 30, 2026 reached USD 23.8 million against USD 8.3 million a year earlier, driven by USD 20.9 million of license revenue from a January 2026 US licensing agreement.
- The third-quarter net loss narrowed to USD 5.8 million from USD 9.6 million, while quarterly revenue slipped to USD 2.3 million from USD 3.1 million as product revenue fell to USD 0.6 million.
- Cash stood at USD 5.5 million on September 30, 2026, and the accumulated Deficit was USD 409.5 million, with the filing stating substantial doubt about the company's ability to continue as a going concern.
- Total liabilities dropped to USD 13.9 million from USD 57.0 million at year-end, after notes payable fell to USD 2.5 million from USD 42.5 million (calculated from current and non-current balances).
A License Payment Drives the Nine-Month Turnaround
Jaguar Health (NASDAQ:JAGX) filed its Quarterly Report on November 16, 2026 for the period ended September 30, 2026. The company, through its Subsidiary Napo, focuses on human health and commercializes Mytesi, an FDA-approved crofelemer tablet for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Nine-month license revenue was USD 20.9 million, compared with USD 0.1 million, while product revenue fell to USD 2.9 million from USD 8.1 million. Operating expenses declined to USD 27.3 million from USD 32.9 million, which left a nine-month loss from operations of USD 3.4 million versus USD 24.7 million.
Third Quarter Shows What the Business Earns Without the Upfront Fee
The quarter itself looks weaker on the top line. Total revenue was USD 2.3 million, down from USD 3.1 million, and product revenue dropped to USD 0.55 million from USD 3.0 million. License revenue of USD 1.8 million partly offset that. Sales and Marketing expense collapsed to USD 0.05 million from USD 2.0 million, which helped trim operating expenses to USD 8.4 million from USD 10.3 million. The quarterly loss from operations was USD 6.0 million, and the net loss was USD 5.8 million, or USD 9.23 a share after the reverse splits.
Going-Concern Doubt Persists Despite a Cleaner Balance Sheet
The company states that its cash is not enough to fund its operating plan for one year, and management concluded its plans do not remove substantial doubt. Operating cash use was only USD 1.4 million for the nine months, compared with USD 18.2 million, mainly because of the license payments. Financing included USD 6.3 million of net proceeds from at-the-market stock sales. Reverse splits of 1-for-35 on April 30 and 1-for-15 on September 17, 2026 reshaped the share count, and 2,132,660 common shares were outstanding at quarter end.
Where Things Stand
The loss narrowed because a one-time USD 20.9 million license arrangement lifted nine-month revenue, not because the product business improved, which answers how the headline loss shrank. Jaguar Health (NASDAQ:JAGX) still reports only USD 5.5 million of cash and an accumulated deficit of USD 409.5 million. After quarter end, the filing says 11,213,326 shares were issued, and on October 2, 2026 the board declared a Special Dividend of one Series R preferred share per common share. Future funding, further share issuance and product sales under the new licensee will shape the next report.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...